PNK 007

Drug Profile

PNK 007

Alternative Names: PNK-007

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Multiple myeloma

Most Recent Events

  • 01 Jan 2017 Celgene initiates enrolment in a phase I trial for Multiple myeloma (Newly-diagnosed, Second-line herapy or greater) in USA (NCT02955550)
  • 14 Nov 2016 Celgene Corporation plans a phase I trial for Multiple myeloma (Newly-diagnosed, Second-line herapy or greater) in USA (NCT02955550)
  • 01 Jun 2016 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT02781467)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top